|
US5863782A
(en)
|
1995-04-19 |
1999-01-26 |
Women's And Children's Hospital |
Synthetic mammalian sulphamidase and genetic sequences encoding same
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
WO2003057179A2
(en)
|
2002-01-11 |
2003-07-17 |
Biomarin Pharmaceutical, Inc. |
Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
|
US20050142141A1
(en)
|
2002-11-27 |
2005-06-30 |
Pardridge William M. |
Delivery of enzymes to the brain
|
|
AU2003286870A1
(en)
|
2003-06-05 |
2005-01-04 |
Salk Institute For Biological Studies |
Targeting polypeptides to the central nervous system
|
|
CA2711590C
(en)
|
2008-01-18 |
2021-03-23 |
Biomarin Pharmaceutical Inc. |
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
|
|
EP2394667A1
(en)
|
2010-06-10 |
2011-12-14 |
Laboratorios Del Dr. Esteve, S.A. |
Vectors and sequences for the treatment of diseases
|
|
PT3103469T
(pt)
|
2010-06-25 |
2021-03-04 |
Shire Human Genetic Therapies |
Administração de agentes terapêuticos no snc
|
|
JP6073783B2
(ja)
|
2010-06-25 |
2017-02-01 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
AU2012294673B2
(en)
|
2011-08-05 |
2015-11-26 |
Bioasis Technologies Inc. |
p97 fragments with transfer activity
|
|
CA3140358A1
(en)
|
2012-07-31 |
2014-02-06 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
|
HUE045144T2
(hu)
|
2012-08-29 |
2019-12-30 |
Hoffmann La Roche |
Véragygát-shuttle
|
|
AU2014243816B2
(en)
|
2013-03-13 |
2019-01-31 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
|
EP2970940B1
(en)
|
2013-03-14 |
2018-07-25 |
Translate Bio, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
|
JP6692293B2
(ja)
|
2013-07-22 |
2020-05-13 |
アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． |
Ｃｎｓにおける酵素活性を増大するための方法および組成物
|
|
SI2970413T1
(sl)
|
2014-04-01 |
2018-10-30 |
Swedish Orphan Biovitrum Ab (Publ) |
Modificirana sulfamidaza in proizvodja le-te
|
|
DK3215528T3
(da)
|
2014-11-06 |
2019-10-07 |
Hoffmann La Roche |
Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
|
|
WO2016081640A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
EA039366B1
(ru)
|
2015-06-24 |
2022-01-19 |
Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. |
Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
|
|
HUE057952T2
(hu)
|
2015-06-24 |
2022-06-28 |
Hoffmann La Roche |
Anti-transzferrin receptor antitestek testreszabott affinitással
|
|
DK3386534T3
(da)
|
2015-12-08 |
2020-11-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
AR107483A1
(es)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
Conjugado de enzimas terapéuticas
|
|
MX2018010196A
(es)
|
2016-02-24 |
2018-11-19 |
Biomarin Pharm Inc |
Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
|
|
EP3494216B1
(en)
|
2016-08-06 |
2025-10-15 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
|
SG11201901495YA
(en)
|
2016-08-25 |
2019-03-28 |
Jcr Pharmaceuticals Co Ltd |
Method for producing antibody fusion protein
|
|
US20190352335A1
(en)
|
2016-12-19 |
2019-11-21 |
Hanmi Pharm. Co., Ltd. |
Brain targeting long-acting protein conjugate
|
|
KR102497564B1
(ko)
|
2016-12-26 |
2023-02-07 |
제이씨알 파마 가부시키가이샤 |
혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
|
|
AU2017386888B2
(en)
|
2016-12-28 |
2024-08-08 |
Jcr Pharmaceuticals Co., Ltd. |
Lyophilized preparation
|
|
WO2018152285A1
(en)
|
2017-02-17 |
2018-08-23 |
Denali Therapeutics Inc. |
Transferrin receptor transgenic models
|
|
CN110506055A
(zh)
|
2017-02-17 |
2019-11-26 |
戴纳立制药公司 |
工程改造的转铁蛋白受体结合多肽
|
|
SG11201907422RA
(en)
|
2017-02-17 |
2019-09-27 |
Denali Therapeutics Inc |
Anti-tau antibodies and methods of use thereof
|
|
GB201702863D0
(en)
|
2017-02-22 |
2017-04-05 |
Evox Therapeutics Ltd |
Improved loading of EVs with therapeutic proteins
|
|
AU2018295994B2
(en)
|
2017-07-07 |
2025-02-06 |
Hanmi Pharm. Co., Ltd. |
Novel therapeutic enzyme fusion protein and use thereof
|
|
EP3665194A4
(en)
|
2017-08-10 |
2021-07-07 |
Denali Therapeutics Inc. |
AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS
|
|
CR20200129A
(es)
|
2017-10-02 |
2020-08-22 |
Denali Therapeutics Inc |
Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
|
|
WO2019094608A1
(en)
|
2017-11-08 |
2019-05-16 |
Denali Therapeutics Inc. |
Anti-bace1 antibodies and methods of use thereof
|
|
CN111511910B
(zh)
|
2017-12-22 |
2024-11-08 |
韩美药品株式会社 |
具有新颖结构的治疗酶融合蛋白及其用途
|
|
TW201934573A
(zh)
|
2018-01-10 |
2019-09-01 |
美商戴納立製藥公司 |
轉鐵蛋白受體結合性多肽及其用途
|
|
WO2019145500A1
(en)
|
2018-01-26 |
2019-08-01 |
Swedish Orphan Biovitrum Ab (Publ) |
Method of treatment
|
|
JP7337099B2
(ja)
*
|
2018-05-25 |
2023-09-01 |
アレクトル エルエルシー |
抗ｓｉｒｐａ抗体およびその使用法
|
|
WO2019246071A1
(en)
|
2018-06-18 |
2019-12-26 |
Denali Therapeutics Inc. |
Fusion proteins comprising progranulin
|
|
WO2020037150A2
(en)
|
2018-08-16 |
2020-02-20 |
Denali Therapeutics Inc. |
Engineered bispecific proteins
|
|
JP2021534220A
(ja)
|
2018-08-22 |
2021-12-09 |
デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. |
抗ｈｅｒ２ポリペプチド及びそれらの使用の方法
|
|
CR20210155A
(es)
*
|
2018-08-31 |
2021-05-10 |
Alector Llc |
Anticuerpos anti-cd33 y métodos para usarlos
|
|
CA3134538A1
(en)
|
2019-04-03 |
2020-10-08 |
Denali Therapeutics Inc. |
Formulations of protein molecules comprising iduronate 2-sulfatase
|
|
WO2021133907A1
(en)
|
2019-12-23 |
2021-07-01 |
Denali Therapeutics Inc. |
Progranulin variants
|
|
PH12022551598A1
(en)
|
2019-12-23 |
2023-11-20 |
Denali Therapeutics Inc |
Progranulin variants
|
|
WO2021146256A1
(en)
|
2020-01-13 |
2021-07-22 |
Denali Therapeutics Inc. |
Anti-trem2 antibodies and methods of use thereof
|
|
JP2023512450A
(ja)
|
2020-01-13 |
2023-03-27 |
デナリ セラピューティクス インコーポレイテッド |
抗ｔｒｅｍ２抗体及びその使用方法
|
|
WO2021158986A1
(en)
|
2020-02-07 |
2021-08-12 |
Denali Therapeutics Inc. |
Methods for the treatment of hunter syndrome
|
|
AU2021224200A1
(en)
|
2020-02-19 |
2022-09-08 |
Denali Therapeutics Inc. |
Engineered anti-HER2 bispecific proteins
|